Ironwood Pharmaceuticals | IRWD - Sales Revenues


Ironwood Pharmaceuticals reported $47.71M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
Almirall EUR 547.63M 12.83M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
Ardelyx USD 110.33M 12.67M Sep/2025
Astellas Pharma JPY 571.21B 46.89B Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Charles River Laboratories USD 994.2M 5.8M Dec/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Exact Sciences USD 878.38M 27.38M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Lexicon Pharmaceuticals USD 1.65M 520K Jun/2024
MacroGenics USD 72.84M 50.6M Sep/2025
Moderna USD 678M 342M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024